Treatment of Latent Tuberculosis Infection
For adults with latent TB infection confirmed by positive interferon-γ release assay or tuberculin skin test and no evidence of active disease, the preferred treatment is a short-course rifamycin-based regimen: either 3 months of once-weekly isoniazid plus rifapentine (12 doses total), 3-4 months of daily isoniazid plus rifampin, or 3-4 months of daily rifampin alone. 1, 2
Preferred Treatment Regimens
The 2020 CDC/National Tuberculosis Controllers Association guidelines prioritize shorter rifamycin-based regimens over traditional isoniazid monotherapy based on superior completion rates and comparable efficacy 2:
First-Line Options (in order of preference):
12 weeks of once-weekly isoniazid (15 mg/kg, max 900 mg) plus rifapentine (weight-based dosing) - This "3HP" regimen offers the advantage of directly observed therapy with only 12 doses and has demonstrated 60-90% efficacy in preventing active TB 1, 3
3-4 months of daily isoniazid plus rifampin - Provides effective treatment with shorter duration than monotherapy 1
3-4 months of daily rifampin alone - Particularly useful for patients who cannot tolerate isoniazid or pyrazinamide 1, 4
Alternative Regimen:
- 6 months of daily isoniazid - Recommended as an alternative for those unable to take shorter preferred regimens due to drug intolerability or drug-drug interactions, particularly in HIV-negative persons 1, 2. While 9 months of isoniazid was previously preferred, the 6-month regimen provides substantial protection with lower hepatotoxicity risk 4
Critical Pre-Treatment Requirements
Before initiating any LTBI treatment, active TB disease must be ruled out through history, physical examination, and chest radiography 1, 4. This is non-negotiable as treating active TB with LTBI regimens risks developing drug resistance 5.
Special Population Considerations
HIV-Infected Patients:
- When isoniazid is chosen, use 9 months rather than 6 months 4
- Rifamycin-based regimens remain preferred options 2
Pregnant Women (HIV-negative):
- Isoniazid daily or twice weekly for 6-9 months is recommended 4
- For women at high risk for progression (HIV-infected or recently infected), do not delay treatment based on pregnancy alone, even in first trimester 4, 6, 4
- Rifampin is not recommended during pregnancy 5
Children and Adolescents:
- Isoniazid for 9 months is the only recommended regimen 5, 4
- Tuberculin skin testing is preferred over interferon-gamma release assays for children under 5 years 7
Drug-Resistant Source Cases:
- Isoniazid-resistant, rifampin-susceptible TB contacts: rifampin plus pyrazinamide for 2 months, or rifampin alone for 4 months 4
- Multidrug-resistant TB contacts: pyrazinamide plus ethambutol OR pyrazinamide plus a quinolone (levofloxacin/ofloxacin) for 6-12 months 4
Clinical Monitoring Requirements
Baseline Assessment:
Baseline liver function testing (AST/ALT and bilirubin) is NOT routinely required for all patients 4, 6, 4. However, baseline testing is mandatory for 4, 6:
- HIV-infected persons
- Pregnant women and those ≤3 months postpartum
- History of chronic liver disease (hepatitis B/C, cirrhosis)
- Regular alcohol use or injection drug users
- Patients taking other hepatotoxic medications
Follow-Up Monitoring:
- Monthly evaluations (in-person or telephone) for patients on isoniazid or rifampin monotherapy 4, 6, 4
- Evaluations at 2,4, and 8 weeks for patients on rifampin plus pyrazinamide 4, 6, 4
- Each visit should assess adherence, symptoms of hepatotoxicity, and other adverse effects 6, 4
Laboratory Monitoring During Treatment:
- Routine monitoring is indicated only for patients with abnormal baseline tests or those at risk for hepatic disease 4, 6
- Discontinue treatment if AST/ALT ≥5 times upper limit of normal without symptoms, or ≥3 times upper limit with symptoms 4, 6
Important Safety Considerations for 3HP Regimen
The once-weekly isoniazid-rifapentine regimen requires specific safety monitoring 3:
- Systemic drug reactions occur in ~5% of patients, typically after the first 3-4 doses, beginning ~4 hours post-ingestion 3
- Hypotension and syncope are rare (2 per 1,000 treated) but serious 3
- Rifapentine induces metabolism of many medications including hormonal contraceptives, methadone, and warfarin 3
- Women using hormonal contraceptives must add or switch to barrier methods 3
- Patients should be educated to report adverse events immediately and stop medication if systemic drug reaction symptoms occur 3
Critical Pitfalls to Avoid
Never add a single drug to a failing regimen - this creates de facto monotherapy and risks developing additional drug resistance 5. If drug resistance is suspected, add ≥2 drugs to which the organism is susceptible 5.
Do not use 2 months of rifampin plus pyrazinamide for LTBI treatment due to unacceptable hepatotoxicity risk, despite earlier recommendations 2. This combination should only be used when treating empirically for active TB disease later determined to be LTBI 2.
Shorter rifamycin-based regimens should not be used when rifamycins are contraindicated due to significant drug-drug interactions 2.
The WHO guidelines strongly recommend systematic testing and treatment for high-risk groups including people living with HIV, contacts of pulmonary TB cases, patients initiating anti-TNF treatment, dialysis patients, transplant candidates, and patients with silicosis 1.